Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Carcinoma, Medullary 14Neoplasm Metastasis 12Neoplasms 10Thyroid Neoplasms 8Breast Neoplasms 8Glioma 6Prostatic Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Colorectal Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Recurrence 2Rectal Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Disease Progression 2

Interventions

veliparib 1vandetanib 1pralsetinib 1osimertinib 1cemiplimab 1alectinib 1Vascular Endothelial Growth Factor A 1Temozolomide 1Sorafenib 1Paclitaxel 1Liquid Biopsy 1GSK3352589 1Docetaxel 1Crizotinib 1Carboplatin 1Capecitabine 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 2a × vandetanib × Clear all
NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
17 enrolled 25 charts
Endocrine

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡